Article
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy.
AIDS (London, England) - 1 Nov 2022
Huik Kristi, Hill Shawn, George Jomy, Pau Alice, Kuriakose Safia, Lange Camille M, Dee Nicola, Stoll Pamela, Khan Muhammad, Rehman Tauseef, Rehm Catherine A, Dewar Robin, Grossman Zehava, Maldarelli Frank
Abstract excerpt
The integrase strand transfer inhibitor (INSTI) dolutegravir is commonly used in combination antiretroviral therapy regimens and retains strong potency even with primary resistance mutations to some other INSTIs. Acquisition of accessory mutations to primary mutations results in significant increases in dolutegravir resistance. Previously, we reported that addition of the secondary mutation T97A can result in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.